PUMA in head and neck cancer

Cancer Letters

Volumn 199, Issue 1, 2003, Pages 75-81

  Hoque, Mohammad Obaidul ^a   Begum, Shahnaz ^b   Sommer, Matthias ^a   Lee, Taekyeol ^a   Trink, Barry ^a   Ratovitski, Edward ^a   Sidransky, David ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

HNSCC; Mutation; p53; PUMA; Tumor suppressor gene

Indexed keywords

PROTEIN P53; TUMOR MARKER;

ALLELE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GENETICS; CANCER INHIBITION; CARCINOGENESIS; CHROMOSOME 19Q; CHROMOSOME DELETION; COLONY FORMATION; CONTROLLED STUDY; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE MAPPING; GENE MUTATION; GENE SEQUENCE; GENE TARGETING; GENETIC CODE; GENETIC PREDISPOSITION; HEAD CANCER; HETEROZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; MICROSATELLITE MARKER; NECK CANCER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUMA GENE; TUMOR SUPPRESSOR GENE; WILD TYPE;

EID: 0042232787     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00344-6     Document Type: Article

References (37)

1. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature. 408:2000;307-310.
2. Vousden K.H. p53: death star. Cell. 103:2000;691-694.
3. Soussi T., Legros Y., Lubin R., Ory K., Schlichtholz B. Multifactorial analysis of p53 alteration in human cancer: a review. Int. J. Cancer. 57:1994;1-9.
4. Harris C.C., Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med. 329:1993;1318-1327.
5. Lane D.P. Cancer p53, guardian of the genome. Nature. 358:1992;15-16.
6. Prives C., Hall P.A. The p53 pathway. J. Pathol. 187:1999;112-126.
7. Maccallum D.E., Hupp T.R., Midgley C.A., Stuart D., Campbell S.J., Harper A., Walsh F.S., Wright E.G., Balmain A., Lane D.P., Hall P.A. The p53 response to ionising radiation in adult and developing murine tissues. Oncogene. 13:1996;2575-2587.
8. Kastan M.B., Zhan Q., El-Deiry W.S., Carrier F., Jacks T., Walsh W.V., Plunkett B.S., Vogelstein B., Fornace A.J. Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 71:1992;587-597.
9. Canman C.E., Wolff A.C., Chen C.Y., Fornace A.J. Jr., Kastan M.B. The p53-dependent G1 cell cycle checkpoint pathway and ataxia- telangiectasia. Cancer Res. 54:1994;5054-5058.
10. Chen C.Y., Oliner J.D., Zhan Q., Fornace A.J. Jr., Vogelstein B., Kastan M.B. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc. Natl. Acad. Sci. USA. 91:1994;2684-2688.
11. Zhan Q., Carrier F., Fornace A.J. Jr. Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol. Cell Biol. 13:1993;4242-4250.
12. Fritsche M., Haessler C., Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene. 8:1993;307-318.
13. Tishler R.B., Calderwood S.K., Coleman C.N., Price B.D. Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res. 53:1993;2212-2216.
14. El-Deiry W.S. Regulation of p53 downstream genes. Semin. Cancer Biol. 8:1998;345-357.
15. Miyashita T., Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80:1995;293-299.
16. Oda E., Ohki R., Murasawa H., Nemoto J., Shibue T., Yamashita T., Tokino T., Taniguchi T., Tanaka N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 288:2000;1053-1058.
17. Oda K., Arakawa H., Tanaka T., Matsuda K., Tanikawa C., Mori T., Nishimori H., Tamai K., Tokino T., Nakamura Y., Taya Y. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by ser-46-phosphorylated p53. Cell. 102:2000;849-862.
18. Yu J., Zhang L., Hwang P.M., Kinzler K.W., Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell. 7:2001;673-682.
19. Johns III M.M., Westra W.H., Califano J.A., Eisele D., Koch W.M., Sidransky D. Allelotype of salivary gland tumors. Cancer Res. 56:1996;1151-1154.
20. Nawroz H., Van Der Riet P., Hruban R.H., Koch W., Ruppert J.M., Sidransky D. Allelotype of head and neck squamous cell carcinoma. Cancer Res. 54:1994;1152-1155.
21. Miura I., Siegfried J.M., Resau J., Keller S.M., Zhou J.Y., Testa J.R. Chromosome alterations in 21 non-small cell lung carcinomas. Genes Chromosomes Cancer. 2:1990;328-338.
22. Mutirangura A., Tanunyutthawongese C., Pornthanakasem W., Kerekhanjanarong V., Sriuranpong V., Yenrudi S., Supiyaphun P., Voravud N. Genomic alterations in nasopharyngeal carcinoma: loss of heterozygosity and Epstein-Barr virus infection. Br. J. Cancer. 76:1997;770-776.
23. Sanchez-Cespedes M., Ahrendt S.A., Piantadosi S., Rosell R., Monzo M., Wu L., Westra W.H., Yang S.C., Jen J., Sidransky D. Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res. 61:2001;1309-1313.
24. Wong M.P., Lam W.K., Wang E., Chiu S.W., Lam C.L., Chung L.P. Primary adenocarcinomas of the lung in nonsmokers show a distinct pattern of allelic imbalance. Cancer Res. 62:2002;4464-4468.
25. Nawroz H., Koch W., Anker P., Stroun M., Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat. Med. 2:1996;1035-1037.
26. Ahrendt S.A., Halachmi S., Chow J.T., Wu L., Halachmi N., Yang S.C., Wehage S., Jen J., Sidransky D. Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc. Natl. Acad. Sci. USA. 96:1999;7382-7387.
27. Nakano K., Vousden P.U.M.A. novel proapoptotic gene, is induced by p53. Mol. Cell. 7:2001;683-694.
28. Sidransky D., Von Eschenbach A., Tsai Y.C., Jones P., Summerhayes I., Marshall F., Paul M., Green P., Hamilton S.R., Frost P., et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science. 252:1991;706-709.
29. Cairns P., Polascik T.J., Eby Y., Tokino K., Califano J., Merlo A., Mao L., Herath J., Jenkins R., Westra W., et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat. Genet. 11:1995;210-212.
30. Merlo A., Herman J.G., Mao L., Lee D.J., Gabrielson E., Burger P.C., Baylin S.B., Sidransky D. CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1:1995;686-692.
31. Li Y.J., Laurent-Puig P., Salmon R.J., Thomas G., Hamelin R. Polymorphisms and probable lack of mutation in the WAF1-CIP1 gene in colorectal cancer. Oncogene. 10:1995;599-601.
32. Mayr B., Wilhelm B., Reifinger M., Brem G. Absence of p21 WAF1 and p27 kip1 gene mutations in various feline tumours. Vet. Res. Commun. 24:2000;115-124.
33. Shiohara M., El-Deiry W.S., Wada M., Nakamaki T., Takeuchi S., Yang R., Chen D.L., Vogelstein B., Koeffler H.P. Absence of WAF1 mutations in a variety of human malignancies. Blood. 84:1994;3781-3784.
34. Gaidano G., Vivenza D., Forconi F., Capello D., Gloghini A., Bhatia K., Gutierrez M., Gallicchio M., Avanzi G.C., Fassone L., Ariatti C., Buonaiuto D., Cingolani A., Saglio G., Tirelli U., Larocca L.M., Dalla-Favera R., Carbone A. Mutation of BAX occurs infrequently in acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Genes Chromosomes Cancer. 27:2000;177-182.
35. Martini M., D'alo F., Pierconti F., Ricci R., Capelli A., Leone G., Larocca L.M. Bax mutations are an infrequent event in indolent lymphomas and in mantle cell lymphoma. Haematologica. 85:2000;1019-1023.
36. Peng H., Aiello A., Packham G., Isaacson P.G., Pan L. Infrequent Bax gene mutations in B-cell lymphomas. J. Pathol. 186:1998;378-382.
37. Sanchez-Cespedes M., Parrella P., Esteller M., Nomoto S., Trink B., Engles J.M., Westra W.H., Herman J.G., Sidransky D. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res. 62:2002;3659-3662.